[1] 中华医学会心血管病学分会, 中国医师协会心血管内科医师分会, 中国医师协会心力衰竭专业委员会, 等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志, 2024, 52(3):235-275. [2] HAO G, WANG X, CHEN Z, et al. Prevalence of heart failure and left ventricular dysfunction in China:the China Hypertension Survey, 2012-2015[J]. Eur J Heart Fail, 2019, 21(11):1329-1337. [3] PONIKOWSKI P, VOORS A A, ANKER S D, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur Heart J, 2016, 37(27):2129-2200. [4] WHO. Medication safety in polypharmacy[R]. Geneva, Switzerland:World Health Organization, 2019. [5] 许顶立, 宋霖. 《中国心力衰竭诊断和治疗指南2024》解读[J]. 临床心血管病杂志, 2024, 40(6):437-439. [6] MCDONAGH T A, METRA M, ADAMO M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Fail, 2022, 24(1):4-131. [7] NAVID P, NGUYEN L, JABER D,et al.Attitudes toward deprescribing among adults with heart failure with preserved ejection fraction[J]. J Am Geriatr Soc, 2021, 69(7):1948-1955. [8] 李莹, 钱玉英, 李耘, 等. 老年人多重用药及评价工具的研究进展[J]. 中华老年多器官疾病杂志, 2021, 20(3):229-232. [9] 蹇在金, 王翼. 老年人多重用药的评估与干预[J]. 中华老年医学杂志, 2019, 38(10):1097-1100. [10] FRIED T R, O’LEARY J, TOWLE V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults:a systematic review[J]. J Am Geriatr Soc, 2014, 62(12):2261-2272. [11] URFER M, ELZI L, DELL-KUSTER S, et al. Intervention to improve appropriate prescribing and reduce polypharmacy in elderly patients admitted to an internal medicine unit[J]. PLoS One, 2016, 11(11):e0166359. [12] GUTHRIE B, MAKUBATE B, HERNANDEZ-SANTIAGO V, et al. The rising tide of polypharmacy and drug-drug interactions:population database analysis 1995-2010[J]. BMC Med, 2015, 13:74. [13] 韦当, 王聪尧, 肖晓娟, 等. 指南研究与评价(AGREEⅡ)工具实例解读[J]. 中国循证儿科杂志, 2013, 8(4):316-319. [14] 王春青, 胡雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30(11):964-967. [15] FOSTER M J, SHURTZ S. Making the critical appraisal for summaries of evidence (CASE) for evidence-based medicine (EBM):critical appraisal of summaries of evidence[J]. J Med Libr Assoc, 2013, 101(3):192-198. [16] ROCHON P A. Drug prescribing for older adults[EB/OL]. (2025-04-11)[2025-06-18]. https://www.uptodate.com/contents/drug-prescribing-for-older-adults. [17] Scottish Intercollegiate Guidelines Network(SIGN). Management of chronic heart failure[EB/OL].Edinburgh:SIGN,2016.(SIGN publication no.147). http://www.sign.ac.uk. [18] COLE J A, GONÇALVES-BRADLEY D C, ALQAHTANI M, et al. Interventions to improve the appropriate use of polypharmacy for older people[J]. Cochrane Database Syst Rev, 2023, 10(10):CD008165. [19] GALLAGHER C, NYFORT-HANSEN K, ROWETT D, et al. Polypharmacy and health outcomes in atrial fibrillation:a systematic review and meta-analysis[J]. Open Heart, 2020, 7(1):e001257. [20] BEEZER J, AL HATRUSHI M, HUSBAND A, et al. Polypharmacy definition and prevalence in heart failure:a systematic review[J]. Heart Fail Rev, 2022, 27(2):465-492. [21] PROKOPIDIS K, TESTA G D, VERONESE N, et al. What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis[J]. J Frailty Sarcopenia Falls, 2024, 9(1):51-65. [22] MUTH C, BLOM J W, SMITH S M, et al. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy:a systematic guideline review and expert consensus[J]. J Intern Med, 2019, 285(3):272-288. [23] 国家重点研发项目(2018YFC2002400)课题组, 中国老年医学学会医养结合促进委员会. 高龄老年共病患者多重用药安全性管理专家共识[J]. 中华保健医学杂志,2021,23(5):548-554. [24] 中华医学会老年医学分会心血管疾病学组, 《老年慢性心力衰竭诊治中国专家共识》编写组. 老年人慢性心力衰竭诊治中国专家共识(2021)[J]. 中华老年医学杂志, 2021, 40(5):550-561. [25] 王增武. 老年心血管病多学科诊疗共识[J]. 中国合理用药探索, 2022, 19(11):1-32. [26] STOLFOL D, IACOVIELLO M, CHIONCELO, et al. How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC[J]. Eur J Heart Fail, 2025, 27(5):747-759. |